Crenolanib

DRUG11 trials

Sponsors

St. Jude Children's Research Hospital, Arog Pharmaceuticals, Inc., University of Ulm

Conditions

Acute Myeloid LeukemiaDiffuse Intrinsic Pontine GliomaEsophagogastric AdenocarcinomaGIST With D842V Mutated PDGFRA GeneNewly Diagnosed AML With FLT3 Activating MutationsNewly Diagnosed FLT3 Mutated AMLProgressive or Refractory High-Grade GliomaRecurrent/Refractory Glioblastoma

Phase 1

PDGFR Inhibitor Crenolanib in Children/Young Adults With Diffuse Intrinsic Pontine Glioma or Recurrent High-Grade Glioma

CompletedNCT01393912

St. Jude Children's Research HospitalDiffuse Intrinsic Pontine Glioma, Progressive or Refractory High-Grade Glioma

Start: 2011-07-31End: 2016-10-31Updated: 2017-04-26

Crenolanib in Combination With Sorafenib in Patients With Refractory or Relapsed Hematologic Malignancies

CompletedNCT02270788

St. Jude Children's Research HospitalAcute Myeloid Leukemia

Start: 2015-04-02End: 2016-10-17Updated: 2017-10-03

Pilot Study of Crenolanib Combined With Standard Salvage Chemotherapy in Subjects With R/R AML

CompletedNCT02626338

Arog Pharmaceuticals, Inc.Relapsed/Refractory Acute Myeloid Leukemia (AML)

Start: 2016-02-29End: 2018-02-28Updated: 2023-12-20

Study of Crenolanib With Ramucirumab and Paclitaxel for Advanced Esophagogastric Adenocarcinoma

CompletedNCT03193918

Arog Pharmaceuticals, Inc.Esophagogastric Adenocarcinoma

Start: 2017-04-14End: 2020-07-15Updated: 2020-07-20

Phase 2

A Safety and Tolerability Study of Crenolanib in Combination With Chemotherapy in Newly Diagnosed Acute Myeloid Leukemia Patients With FLT3 Mutations

CompletedNCT02283177

Arog Pharmaceuticals, Inc.Newly Diagnosed AML With FLT3 Activating Mutations

Start: 2015-01-31End: 2019-12-31Updated: 2024-02-02

Study of Crenolanib in Recurrent/Refractory Glioblastoma With PDGFRA Gene Amplification

CompletedNCT02626364

Arog Pharmaceuticals, Inc.Recurrent/Refractory Glioblastoma

Start: 2016-04-30End: 2020-07-31Updated: 2020-07-20

A Study of Crenolanib With Fludarabine and Cytarabine in Pediatric Patients With Relapsed/Refractory FLT3-Mutated Acute Myeloid Leukemia

WithdrawnNCT03324243

Arog Pharmaceuticals, Inc.Relapsed/Refractory FLT3-mutated AML

Start: 2018-01-31End: 2020-12-31Updated: 2019-01-10

Phase 3

Study of Crenolanib in Combination With Chemotherapy in Patients With Relapsed or Refractory Acute Myeloid Leukemia and Activating FLT3 Mutations

TerminatedNCT02298166

University of UlmAcute Myeloid Leukemia

Start: 2016-11-17End: 2020-03-09Updated: 2021-10-06

Randomized Trial of Crenolanib in Subjects With D842V Mutated GIST

Arog Pharmaceuticals, Inc.GIST With D842V Mutated PDGFRA Gene

Start: 2016-08-31End: 2021-08-31Target: 120Updated: 2021-01-22

Study Investigating the Efficacy of Crenolanib With Chemotherapy vs Chemotherapy Alone in R/R FLT3 Mutated AML

CompletedNCT03250338

Arog Pharmaceuticals, Inc.Relapsed/Refractory Acute Myeloid Leukemia With FLT3 Activating Mutations

Start: 2018-08-16End: 2026-04-03Updated: 2026-04-09

Study of Crenolanib vs Midostaurin Following Induction Chemotherapy and Consolidation Therapy in Newly Diagnosed FLT3 Mutated AML

CompletedNCT03258931

Arog Pharmaceuticals, Inc.Newly Diagnosed FLT3 Mutated AML

Start: 2018-08-15End: 2026-04-06Updated: 2026-04-09

Related Papers

Crenolanib plus salvage chemotherapy improves outcomes in FLT3-mutant and NPM1 co-mutated relapsed/ refractory (R/R) Acute Myeloid Leukemia (AML): Results from a randomized, placebo-controlled, double-blind trial

Blood2025-11-03

Long-term results of a phase 2 trial of crenolanib combined with 7+3 chemotherapy in adults with newly diagnosed FLT3 mutant AML.

Journal of Clinical Oncology2022-06-0110 citations

Midostaurin plus intensive chemotherapy for younger and older patients with AML and <i>FLT3</i> internal tandem duplications

Blood Advances2022-04-2967 citations

Population pharmacokinetics of crenolanib in children and young adults with brain tumors.

2022-02-252 citations

Phase I/Ib study of crenolanib with ramucirumab and paclitaxel as second-line therapy for advanced esophagogastric adenocarcinoma.

2022-01-232 citations

Younger Patients with Newly Diagnosed FLT3-Mutant AML Treated with Crenolanib Plus Chemotherapy Achieve Adequate Free Crenolanib Levels and Durable Remissions

Blood2019-11-1314 citations

Tolerability and Efficacy of Crenolanib and Cytarabine/Anthracycline Chemotherapy in Older Patients (Aged 61 to 75) with Newly Diagnosed FLT3-Mutated Acute Myeloid Leukemia (AML)

Blood2019-11-1314 citations

Crenolanib versus midostaurin combined with induction and consolidation chemotherapy in newly diagnosed <i>FLT3</i> mutated AML.

Journal of Clinical Oncology2019-05-209 citations

A phase I/Ib study of crenolanib with ramucirumab (RAM)/paclitaxel (PTX) as second-line therapy (2L tx) for advanced esophagogastric adenocarcinoma (EGA).

Journal of Clinical Oncology2019-01-292 citations

Addition of Crenolanib to Induction Chemotherapy Overcomes the Poor Prognostic Impact of Co- Occurring Driver Mutations in Patients with Newly Diagnosed FLT3-Mutated AML

Blood2018-11-2912 citations

Safety Analysis of Intra-Patient Dose- Study of Crenolanib Maintenance Therapy in Patients with FLT3 Mutant AML Following Allogeneic Hematopoietic Stem Cell Transplant

Blood2018-11-296 citations

Proportion of Patients with FLT3 Positive AML Required to Enroll on Clinical Trials to Satisfy the Recruitment Needs of FLT3 Inhibitor Trials: Are We Running out of Patients?

Blood2018-11-29

A randomized, double-blind, placebo-controlled, phase III study of crenolanib in advanced or metastatic GIST patients bearing a D842V mutation in <i>PDGFRA</i>: The CrenoGIST study.

Journal of Clinical Oncology2017-05-2011 citations

Effect of cytarabine/anthracycline/crenolanib induction on minimal residual disease (MRD) in newly diagnosed FLT3 mutant AML.

Journal of Clinical Oncology2017-05-207 citations

First-in-pediatrics phase I study of crenolanib besylate (CP-868,596-26) administered during and after radiation therapy (RT) in newly diagnosed diffuse intrinsic pontine glioma (DIPG) and recurrent high-grade glioma (HGG).

Journal of Clinical Oncology2014-05-208 citations